about
A2B adenosine receptor activity is reduced in neutrophils from patients with systemic sclerosisSalivary Gland Ultrasonography in Sjögren's Syndrome: Clinical Usefulness and Future PerspectivesEULAR Sjögren's syndrome disease activity index (ESSDAI): a user guideA model of anti-angiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients.Correlations of Y chromosome microchimerism with disease activity in patients with SLE: analysis of preliminary data.Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study.Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation.EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.Blunted increase of digital skin vasomotion following acetylcholine and sodium nitroprusside iontophoresis in systemic sclerosis patients.Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations.Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis.A case of undifferentiated connective tissue disease: is it a distinct clinical entity?Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.Muscle modifications in fibromyalgic patients revealed by surface electromyography (SEMG) analysis.High dose intravenous immunoglobulin therapy for rheumatic diseases: clinical relevance and personal experience.[Italian consensus on the recommendations about the use of methotrexate for the treatment of rheumatic diseases with a focus on rheumatoid arthritis: results from the "3E initiative"]Lung involvement in Sjögren's syndrome: a comparison between patients with primary and with secondary syndrome.HLA antigens in Italian patients with primary Sjögren's syndromeThe European Community Study Group on diagnostic criteria for Sjögren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren's syndrome.Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome.Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria.Polymyositis occurring during alpha-interferon treatment for malignant melanoma: a case report and review of the literature.Increased finger skin vasoreactivity and stimulated vasomotion associated with simvastatin therapy in systemic sclerosis hypercholesterolemic patients.Cellular adhesion gene SELP is associated with rheumatoid arthritis and displays differential allelic expression.Proteomic analysis of saliva: a unique tool to distinguish primary Sjögren's syndrome from secondary Sjögren's syndrome and other sicca syndromesEULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs.[MALDI-TOF and SELDI-TOF analysis: "tandem" techniques to identify potential biomarker in fibromyalgia].European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studiesMixed cryoglobulinemia and hepatitis C virus association: ten years later.Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias.Alteration of microcirculation is a hallmark of very early systemic sclerosis patients: a laser speckle contrast analysis.Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study.Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus GroupFunctional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus.Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients.Treatment of chronic hepatitis C infection with cryoglobulinemia.Preliminary classification criteria for the cryoglobulinaemic vasculitis.American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.The targets of nephritogenic antibodies in systemic autoimmune disorders.
P50
Q24803585-C8B11F57-4090-44D0-92D3-C38FFC1CBCB9Q26745735-1709DB7C-ED6E-4C65-947E-81398B5B5656Q26778262-19E68532-C2F5-4EC0-9E4F-5A9594F56607Q30478833-4D6EF7D6-66BF-48E9-9571-8FB0650D73ACQ30804232-23764FA0-2062-41C5-AFD4-7074602E12B7Q30985919-A12EAB51-7CE4-4539-90A0-7BEE782BDF53Q32175831-AC60F802-46CC-4BB8-9D1D-77C98A52EF7CQ33284736-9449C476-5CE3-4615-9991-BD0A15DB2BADQ33330236-6DEB212A-3035-40AE-81F8-54EFBA173DBDQ33341941-EF86575B-5B39-4D06-829C-3CD17A7A07BBQ33369384-C76737A1-EA27-4217-A9E7-87C5E77E2B61Q33369386-7AB232CA-9C7F-40A2-941B-66B5C76C394BQ33379279-973B8652-0FF8-47FC-A730-D8FB5CA5B1A3Q33412915-500B0115-7B40-4EEE-848B-3143101314D2Q33430481-3E476847-5C2F-46B3-BF7F-E0DE0B64E9D5Q33497024-9B60029C-A167-4652-AE21-5A7E8DF705BBQ33555183-2ACCFAE4-3A1B-4AC4-AA66-6D61EC217F29Q33555980-2E7247CE-AA92-4F0A-A8F2-030E6B3D6FBFQ33556641-002ADDA5-CBDC-4A5C-8939-F878EFE6B04CQ33566683-593F2DD1-6B28-497F-8E83-C1836DDCC15BQ33578726-E9CB2C57-E14F-4EF1-A78D-59A36C0378E9Q33764183-FD94443F-6691-4844-8B93-753847B2F8F6Q33825952-04EC8143-7AA1-461B-9F13-35028D8A7674Q34068022-8DEA6DEB-05AB-432B-B5AD-E460CE34062AQ34078388-7D9E91E2-D4B0-48C8-9A7D-46CAE289147AQ34083843-D3398CAA-C793-45F9-93C8-BB54F165EF52Q34132211-E428F524-99F5-4982-A22F-54B8FB22383CQ34132637-BDAC3C0F-3192-417E-8FA3-9E36938B51D5Q34187282-8B58979C-6DDF-4257-9574-B26C39C14F9CQ34297196-822E523E-37C7-4403-AD47-4F0B73D9A3D7Q34307681-816DD61C-C111-43ED-ACC5-7219D9E54D7AQ34448781-4B003F0C-6189-4C0F-BBC6-03CF51171D46Q34486262-5AEEE21C-E31D-49FC-A862-F3CD27C6C5DBQ34523084-1BB35C54-5BE8-446A-8BE0-95CB7D92F9F4Q34553202-518991A0-23A8-4A7D-806B-62D68E046772Q34559161-07069EA9-57D7-4500-AB0F-B5E0AFD36F4AQ34618154-355C42FD-592F-4CC4-96AB-E045FF9975C5Q35012168-5E6809F4-645B-437D-AA9F-B9E65F9A13D2Q35047250-FC9D59EC-6401-45BB-B5E0-7C1B9376F03BQ35172156-3715F35B-F53B-4F1E-9A81-A56F4B2E7BF5
P50
description
forsker
@nb
researcher
@en
ricercatore
@it
name
Stefano Bombardieri
@da
Stefano Bombardieri
@de
Stefano Bombardieri
@en
Stefano Bombardieri
@fr
Stefano Bombardieri
@nb
Stefano Bombardieri
@nl
Stefano Bombardieri
@nn
Stefano Bombardieri
@sv
type
label
Stefano Bombardieri
@da
Stefano Bombardieri
@de
Stefano Bombardieri
@en
Stefano Bombardieri
@fr
Stefano Bombardieri
@nb
Stefano Bombardieri
@nl
Stefano Bombardieri
@nn
Stefano Bombardieri
@sv
prefLabel
Stefano Bombardieri
@da
Stefano Bombardieri
@de
Stefano Bombardieri
@en
Stefano Bombardieri
@fr
Stefano Bombardieri
@nb
Stefano Bombardieri
@nl
Stefano Bombardieri
@nn
Stefano Bombardieri
@sv
P214
P106
P21
P214
P31
P3901
P569
1968-01-01T00:00:00Z
P7859
lccn-no2009081683